Geron Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Oct 30 Calls Today's Calls

Call Details Geron Earnings Conference Call (Q3 2009) Fri, Oct 30, 2009, 11:00 am Eastern Listen to the archived event audio About Geron (NasdaqGM:GERN) Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, as well as focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. Its products include GRN163 and GRN163L, which are telomerase inhibitors for the treatment of chronic lymphoproliferative diseases, solid tumors, non-small cell-lung cancer, breast cancer, and multiple myeloma, which are in Phase I trials; and GRNVAC1, a telomerase cancer vaccine that is in Phase II clinical trial for the treatment of acute myelogenous leukemia. Geron Corporation also develops human embryonic stem cell-based therapeutics, with its spinal cord injury treatment. The company has research, development, and commercialization license agreement with Merck & Co., Inc. to use telomerase in non-dendritic cell cancer vaccines; and a license agreement with Sienna Cancer Diagnostics to detect telomerase for in vitro cancer diagnosis. Geron Corporation was founded in 1990 and is based in Menlo Park, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings